Released Aug 5, 2019, after the close
10-Q filed Aug 5, 2019, 36 days after period end · 0001144204-19-037687
Q2 2019 · 10-Q
Revenue$3.08M$3.08M −4.3% vs Q2 2018−20.7% vs Q1 2019
Net Income-$18.50M-$18.50M N/M vs Q2 2018N/M vs Q1 2019
EPS Diluted-$0.72-$0.72 N/M vs Q2 2018N/M vs Q1 2019
Operating Income-$19,700,000N/M
Operating Cash Flowderived-$21,005,000N/M
Free Cash Flowderived-$21,056,000N/M
Margins · derived
Operating margin-639.6%+204.6 pt vs Q2 2018
Net margin-600.7%+232.3 pt vs Q2 2018
What the release said
The release
Same quarter
| Metric | Q2 2019 | Q2 2018 | Q2 2017 | Q2 2016 |
|---|---|---|---|---|
| Revenue | $3.08M | $3.22M | $2.36M | — |
| Net Income | -$18.50M | -$26.81M | -$13.60M | -$10.15M |
| EPS Diluted | -$0.72 | -$1.30 | -$780.00 | -$0.59 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR